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moderate risk, sunscreen only is recommended. For patient 
groups with high and very high risk, a very high photopro-
tection and photorepair action (DNA repair enzymes) in 
medical device products all year round is recommended. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Actinic keratosis (AK) is a common skin disease char-
acterized by lesions of epidermal dysplasia appearing on 
skin chronically exposed to solar radiation such as the 
head, scalp, face, forearms, and backs of the hands, pri-
marily in persons with Fitzpatrick skin types I, II and III. 
In Australia, AK is found in 40–50% of the Caucasian 
population over the age of 40 years  [1] and reported as 
40–60% by Frost and Green  [2] . The prevalence in the 
USA ranges from 11 to 26%  [3] , whilst in Europe 15% of 
men and 6% of women have been reported to be affected 
 [3] . In Germany a recent study estimated the standard-
ized prevalence of AK from dermatological examinations 
at 2.7%, with prevalence increasing with age (11.5% in the 
group 60–70 years)  [4] . The prevalence, which is at the 
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 Abstract 
 Actinic keratosis (AK) or lesions of epidermal dysplasia oc-
curring in skin chronically exposed to solar radiation is very 
prevalent in lighter skin persons, with chronic long-term sun 
exposure being the major risk factor. With an aging popula-
tion it is expected that the prevalence of AK will further in-
crease. AK can progress to nonmelanoma skin cancer 
(NMSC) and is a public health concern. Six leading derma-
tologists with expertise in AK and NMSC from Germany met 
to discuss the nature of the disease and the prevention and 
treatment strategies available to dermatologists today. 
While cosmetic sunscreen products form an essential ele-
ment of sun protection strategies, they are not adequate 
when damage has already been inflicted. Newly developed 
products of the medical device category offer DNA repair 
function paired with high sun protection factor (SPF) UV 
protection. An adjuvant treatment algorithm for various
risk levels of AK was developed. For patients with low and 
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lower limit of studies from other countries, suggests about 
1.7 million estimated AK cases documented by derma-
tologists in Germany. In 2011, AK accounted for 8.3% of 
the 100 most frequently treated dermatological outpa-
tient diagnoses in Germany, with the proportion of AK 
cases rising almost continuously over the last 10 years 
compared to other dermatological conditions  [4] . Chron-
ic long-term sun exposure is the major risk factor for AK 
 [5] . In Germany, the medical consultation board of ‘oc-
cupational diseases’ of the Ministry of Labor and Social 
affairs has investigated the association between occupa-
tional UV irradiation and skin cancer risk. Recently, the 
following new occupational disease was added to appen-
dix 1 of the German ordinance on occupational diseases 
(Berufskrankheitenverordnung, BKV): ‘squamous cell 
carcinoma and multiple actinic keratosis due to natural 
UV irradiation’  [6] . Published epidemiological studies 
show that cumulative occupational exposure is a substan-
tial and robust risk factor for the development of cutane-
ous squamous cell carcinoma (SCC)  [7] . These findings 
are of significant public health impact as they highlight 
the need for preventive measures for individuals with 
high levels of work-related UV radiation exposure  [7] . 
Outdoor workers, as in agriculture, forestry, seafaring, 
construction, and road maintenance, have a greater oc-
cupational exposure to UV. An additional occupational 
UV exposition of 40% is assumed to double the risk of 
skin cancer and is thus legally relevant for the pathogen-
esis of an occupational disease  [6] . 
 Because of the current demographic development it is 
expected that the incidence of AK will further increase. 
Furthermore, AK is chronic and recurrent in nature, with 
immunosuppressed patients at an even greater risk for 
developing nonmelanoma skin cancer (NMSC). Thus, it 
is a significant economic burden for health care systems. 
As a consequence there is a growing need for the develop-
ment of novel preventive strategies. With this as back-
ground, six experts, all dermatologists, with expertise in 
photodermatology, dermatooncology and dermatoepi-
demiology, met to form an expert panel. Panel members 
were from various German hospitals, university hospitals 
and/or private practice. During the meeting, these experts 
worked on the formalization and writing of this report, 
which was based mainly on the existing literature as well 
as their own practice and experience. The topics dis-
cussed were the molecular basis of AK, progression to 
SCC of AK, risk factors for AK, and existing options for 
the prevention of AK. In particular, recently published 
literature about the efficacy of medical devices was re-
viewed.
 Molecular Events in AK Initiation and AK-to-SCC 
Progression 
 Actinically damaged skin has an accumulation of on-
cogenic mutations leading to a proliferation of atypical 
keratinocytes that may manifest as AK or SCC  [8] . Un-
derlying molecular changes in normal-appearing skin, 
detectable by histology or immunohistochemistry, are 
present before any clinical changes can be observed. The 
pathophysiology associated with UV-damaged skin 
demonstrates that AK is one of the initial events in a dis-
ease progression that can ultimately lead to invasive SCC. 
In this context the term field cancerization is important. 
Field cancerization is defined as a biological process in 
which large areas of cells at a tissue surface or within an 
organ are affected by carcinogenic alterations  [9] . The 
process arises from exposure to an injurious environ-
ment, often over a lengthy period. In the case of AK, field 
cancerization specifically refers to the process whereby 
keratinocytes surrounding the visible lesion are geneti-
cally altered but appear histologically normal. In other 
words, field cancerization is related to cells with cancer-
associated genetic alterations but without invasive 
growth  [10] . The preneoplastic phase in skin is likely to 
reflect an accumulation of mutations that form the basis 
for the carcinogenesis process. Recurrence is more or less 
designated to the (clinical/histological) reappearance of 
remnant tumor nests which then form again as a visible 
(clinically evident) tumor. When a tumor is excised from 
a predisposed epidermis, recurrence may occur. This 
may be due to neoplastic conversion of residual parts of 
field cancerization or, more likely, to the fact that adja-
cent areas with the same extent of UV exposure which 
exhibit the same amount and quality of mutagenic ‘hits’ 
as the already evolved AK also develop visible AK, which 
by definition is then a ‘de novo’ genesis but in a field-
cancerized area. Furthermore, it has been widely report-
ed that after a first tumor occurrence, the chance of re-
currence is statistically enhanced  [11] . In fact, the pres-
ence of AK is associated with a greater than 6-fold 
increase in the risk of developing skin cancers  [12] . Al-
though it is difficult to predict the probability that a spe-
cific AK lesion will convert to more advanced disease, 
reports indicate that SCC originate in lesions previously 
diagnosed as AK, or within a field that contained AK, at 
frequencies ranging from 65 to 97%  [13, 14] . It has re-
cently been shown that cutaneous invasive SCC may also 
directly arise from a proliferation of atypical basaloid 
cells limited mostly to the epidermal basal layer (AK I) 
and not limited to the classical pathway of stepwise pro-
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gression from AK I to AK II to AK III as previously be-
lieved  [15] . This finding suggests that all AK lesions are 
therefore potentially invasive and tumor advance along 
adnexal structures might facilitate invasive SCC develop-
ment from AK I lesions. Notwithstanding the pathway, 
over the course of 10 years, about 10% of AK develop into 
invasive SCC, supporting an estimation of hundreds of 
thousands of patients constantly developing potentially 
metastasizing skin tumors  [16, 17] . The latter, however, 
is a disease stage which is evidently not successfully treat-
able and should therefore be avoided at all costs.
 The basic event in photocarcinogenesis is the induc-
tion of DNA damage by UV radiation. UVA and UVB 
induce primarily two types of DNA lesions – cyclobutane 
pyrimidine dimers (CPD) and (6-4) photoproducts. In-
duction of DNA lesions is a common event, occurring 
upon exposure to rather low, nonerythematogenic doses 
of UVB exposure. The majority of these lesions are usu-
ally removed by nucleotide excision repair (NER), a com-
plex repair process involving over 20 proteins  [18] . The 
efficacy and the importance of NER are best shown by the 
disease xeroderma pigmentosum (XP). Owing to genetic 
mutations in specific components of NER, XP patients 
are severely impaired in their DNA repair capacity and, 
as a consequence, experience a dramatically (1,000-fold) 
increased incidence of skin cancer at early ages  [19] . Mu-
tations in the tumor suppressor gene p53 are believed to 
be a very early if not initial event in skin carcinogenesis 
 [20] . In premalignant lesions and in situ carcinomas, p53 
overexpression is not exclusively restricted to neoplastic 
cells but frequently affects the histologically and clinical-
ly normal-appearing keratinocytes adjacent to p53-posi-
tive neoplasms or present in dysplastic areas  [21] . Muta-
tions of the p53 gene occur early in the sequential devel-
opment of chronically sun-damaged skin, AK and SCC, 
strongly supporting an important role for p53 in UV-
induced skin carcinogenesis. The p53 gene is essential in 
maintaining genomic integrity by blocking DNA replica-
tion in response to DNA damage from exposure to agents 
like UV light. In the presence of an intact p53 gene, cells 
with extensive damage are blocked from entering the cell 
cycle and instead undergo apoptosis. In this regard it 
should be mentioned that visible light as well as near-
infrared radiation can also exert biological effects on
human skin. Whether these are of relevance for photo-
carcinogenesis, however, is currently not known.
 Of note, UV radiation-induced DNA damage also 
causes immunosuppressive effects which are thought to 
additionally contribute to the development of skin cancer 
 [22, 23] .
 Prevention by Sunscreens 
 Ideally, any intervention aimed at preventing and
reversing the photo-induced changes should be able to 
reverse the initial molecular changes caused by UV dam-
age – the very same changes that define the field of can-
cerization. In view of the depth of damage induced by UV 
exposure of the skin, avoidance of sun exposure by stay-
ing out of the sun during the peak hours of UV emission 
should be stressed as the primary step in preventing UV-
induced damage. The use of appropriate protective cloth-
ing reaffirms preventive measures that should be promot-
ed. When UV exposure cannot be limited, sunscreens can 
provide protection against damage caused by UV expo-
sure. In an Australian study with 588 patients, the use of 
sunscreen with a sun protection factor (SPF) of 17 during 
one summer prevented the development of AK and has-
tened the remission of existing ones  [24] . It is now gener-
ally believed that regular use of sunscreens reduces the 
incidence of AK  [24] and new AK lesions  [25] and aids in 
the remission of existing ones in immune-competent 
subjects.
 Although the American Academy of Dermatology rec-
ommends the generous application of a ‘sunscreen with 
SPF of at least 30’ to reduce the incidence of UV-related 
skin cancers, there is evidence that sunscreens with SPF 
>50 provide additional benefit. Accordingly, sunscreens 
with high SPF (SPF  ≥ 70), when applied by consumers at 
typically used amounts, may also provide benefit in ultra-
violet protection by delivering an actual SPF that meets 
the minimum SPF levels recommended for skin cancer 
and photodamage prevention  [26] . In contrast, sun-
screens with SPF 30 or 50 may not produce sufficient pro-
tection at actual consumer usage levels which is generally 
lower than the 2 mg    ·    cm –2 amount that is recommended. 
In fact, an increasing number of studies suggest that the 
actual SPF present on the skin of consumers may be as 
low as 25% of the labeled SPF  [27] .
 In other words, a sunscreen of SPF 50 would provide, 
under real consumer use conditions, an SPF of 12.5, 
which would be lower than the minimum SPF of 15 rec-
ommended by the Food and Drug Administration (USA) 
for the achievement of the prevention of NMSC. In se-
lected cases, the very high SPF (up to 100) sunscreens are 
feasible today due to advances in formulation technology 
that have not only achieved stable formulations but also 
with galenic characteristics that aid consumer compli-
ance. In addition, sunscreens with very high SPF may be 
of benefit for specific subgroups with greater susceptibil-
ity towards UV radiation-induced carcinogenesis. One 
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such group is organ transplant recipients as they are high-
ly susceptible to developing NMSC such as AK, invasive 
SCC and basal cell carcinoma (BCC). In 2009, a study 
with 120 immunocompromised organ transplant recipi-
ents demonstrated that regular use of sunscreen with SPF 
>50 prevented the development of further AK, invasive 
SCC and, to a lesser degree, BCC in these patients  [28] . 
All patients were equally informed on sun protection 
measures, but 60 of these were provided with a free broad-
spectrum study sunscreen (SPF >50, high UVA absorp-
tion) for daily application of 2 mg    ·    cm –2 to the head, neck, 
forearms, and hands. After 24 months, 42 of the 120 pa-
tients had developed 82 new AK (–102 sunscreen group 
vs. +82 control group), 8 new invasive SCC (0 vs. 8) and 
11 new BCC (2 vs. 9). In spite of equal numbers of AK at 
baseline, a marked difference in favor of the intent-to-
treat sunscreen group was recorded after 2 years, and the 
lesion count was significantly lower compared to the ini-
tial visit.
 Apart from the harmful effects of solar radiation a lim-
ited UV exposure is necessary for endogenous vitamin D 
synthesis in the skin  [29] . However, this can be achieved 
by short-term UV exposures of very limited areas of the 
skin – in sunny areas like Florida or California but not in 
Chicago or Northern Europe  [30] . Nevertheless, given 
the carcinogenic risk of UV exposure any further inten-
sive sun exposure or sunbed use should strictly be avoid-
ed and a vitamin D deficiency should be treated with oral 
vitamin D supplementation rather than increased UV ex-
posure.
 Although sunscreens provide protection against UV-
induced DNA damage and resulting biological conse-
quences, they are completely ineffective once the damage 
is sustained. More recently, medical devices containing 
active molecules capable of repairing preexisting DNA 
damage have therefore been developed for the prevention 
of AK.
 Medical Devices for the Prevention and Reversal of 
Actinic Damage 
 Novel approaches tap into natural defense mecha-
nisms from nonhuman species such as bacteria, which 
remove UV radiation-induced DNA damage using an en-
zyme called T4N5 endonuclease V, or marsupials or algae 
that use an enzyme called photolyase. Although not ex-
pressed in human cells, these repair enzymes work equal-
ly well when delivered into human cells through unique 
mechanisms of action. The enzyme T4N5 endonuclease 
V acts by enhancing the NER mechanism that is already 
present in humans although deficient in XP patients. A 
topical application of a T4N5 endonuclease V lotion re-
duced the incidence of skin cancer in chronically UV ra-
diation-exposed mice by enhancing the removal of CPD 
 [31] . The incorporation of these nonhuman repair en-
zymes into special liposomes was later shown to enable 
the penetration of these into human cells and, even more 
importantly, into human skin when applied topically 
 [32] . In 2001 a multicenter double-blinded study in XP 
patients revealed that the application of a T4N5 endonu-
clease-containing lotion significantly reduced the inci-
dence of AK within a period of 1 year  [33] .
 Photolyase is a light-activated flavoenzyme that binds 
specifically to CPD in DNA and repairs them in a reaction 
triggered by electron transfer from the photo-excited fla-
vin cofactor to the dimer. Stege et al.  [34] applied photoly-
ase prepared from  Anacystis nidulans  encapsulated in a 
liposome lotion to the irradiated skin of 19 healthy hu-
man volunteers. Light-exposed photolyase significantly 
reduced the number of UVB-induced CPD in the epider-
mis. After 30 min of exposure to photoreactivating light, 
40–45% of CPD had been removed from the irradiated 
areas of skin. Furthermore, the topical application of this 
xenogeneic DNA repair enzyme was able to prevent UVB 
radiation-induced erythema, keratinocyte apoptosis and, 
most importantly, immunosuppression in vivo  in hu-
mans. Of the two DNA repair enzymes, photolyase in a 
liposomal preparation with photoreactivation restores 
UVB-induced dipyrimidine dimers faster and more ef-
fectively than the topical use of T4 endonuclease V in a 
similar preparation. This difference can be attributed to 
the fact that T4 endonuclease V is one player in a concert 
of multiple NER enzymes. In healthy humans with no de-
ficiency of this repair enzyme system the addition of sin-
gle enzymes may only result in a limited increase of repair 
activity. In contrast, since photoreactivation seems not to 
occur in human skin in the absence of photolyase  [35] , 
the topical application of photolyase and photoreactiva-
tion transiently provides an additional DNA repair sys-
tem to human cells. Therefore, CPD can be very effec-
tively removed by the topical application of xenogeneic 
photolyase, thus protecting human skin from the detri-
mental effects of UVB irradiation. The use of photolyase 
in commercially available sunscreens and after sun prod-
ucts, therefore, can form part of sun protection strategies, 
whereas the use of T4 endonuclease V containing lipo-
somes may be restricted to indications where existing 
DNA repair is defective  [35] . More recently, medical de-
vices containing UV filters in combination with photoly-
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ase have been developed for the prevention of AK. This 
medical device category of products differs from com-
mon sunscreens in that whereas common cosmetic sun-
screens are subject to the European Commission recom-
mendation and do not require an external certification, a 
medical device class II is certified by an independent no-
tified body and fulfills the European requirements of a 
medical device class II. Some human studies have looked 
at the use of one such topical cream which combines pho-
tolyase enzyme in liposomes with very high SPF UV fil-
ters. Of note, in addition to the medical devices men-
tioned above, sunscreens are commercially available 
which also contain DNA repair enzymes such as photo-
lyase.
 Clinical Evidence 
 At least five clinical studies have demonstrated the ef-
fect of a topically applied medical device in cream or flu-
id formulation containing photolyase encapsulated in li-
posomes and UV filters with very high SPF (>100). A 
summary of these studies is provided in  table 1 .
 Puviani et al.  [36] reported a series of 6 patients with 
AK lesions treated with the above-mentioned medical de-
vice, both as coadjuvant or the only treatment, applied 
twice daily in cream or fluid formulation for a mean of 
1–3 months. Clinical photographs of the skin lesions at 
baseline and after treatment showed an improvement of 
the field cancerization, especially of AK lesions.
 Another report presented retrospective data regarding 
the use of the medical device containing photolyase in 8 
XP patients treated for at least 12 consecutive months, 
comparing the rate of new skin lesions (AK, BCC and 
SCC) during active treatment and during 12 months just 
before the use of the medical device  [37] . New NMSC le-
sion numbers during the 1-year treatment with the topi-
cal cream were 5, 3 and 0, respectively, in comparison 
with 14, 6.8 and 3 lesions, respectively, during the 1-year 
pretreatment period. The use of the topical cream was as-
sociated with a 65% reduction of new AK lesions and with 
a 56 and 100% reduction in the incidence of new BCC and 
SCC lesions, respectively, suggesting that the topical use 
of photoprotection and DNA repair enzyme could help 
to decrease the incidence of NMSC in XP  [35] .
 In a third study, 13 patients (11 DNA repair proficient, 
2 of whom were XP patients) older than 50 years with an 
area larger than 3.6 × 3.6 cm affected by multiple AK le-
sions in a sun-exposed skin area were treated for 4 weeks 
with a medical device with photolyase and high SPF UV 
filters or a sunscreen containing UV filters only – both 
with an identical SPF. The patients were instructed to ap-
ply the cream in the morning and 4 h later. A clinical 
evaluation was performed during the treatment, by der-
moscopy and reflectance confocal microscopy (CM), and 
at the beginning and at the end of the treatment by histo-
pathology and at the molecular level using CPD detection 
and RNA expression arrays. The evaluation showed an 
improvement in the AK, reaching a histological clearance 
of AK in 4 cases and an improvement with the presence 
of focal AK associated with inflammation in another 3 
cases. In contrast, no improvement was noted in the 3 
patients who had used the product containing UV filters 
only. The clinical and dermoscopic evaluation demon-
strated a significant improvement of erythema and scal-
ing after 4 weeks of treatment with the medical device 
compared to the control group treated with UV filters 
only. Immunohistochemical analysis of biopsy samples 
before and after treatment showed a decreased expression 
of p21 in the suprabasal layer and a decreased expression 
of proliferating cell nuclear antigen proteins in the basal 
layer  [38] .
 In another publication the same authors evaluated the 
molecular effects of topical cream on the cutaneous field 
of cancerization in 7 AK patients  [39] . This study was 
conducted with the same set of patients reported in the 
study by Puig et al.  [38] , where only 7 patients partici-
pated in this phase of the study. The area assessed for cu-
taneous field of cancerization was divided into four 0.8 × 
0.8 cm subareas. A 3-mm punch biopsy was obtained 
from area 1 for histopathological evaluation and another 
3-mm punch biopsy was taken from area 2 before start-
ing treatment and preserved for RNA extraction. After 4 
weeks of product application, two additional punch biop-
sies were obtained from area 3 for histopathological ex-
amination and from area 4 for additional RNA extrac-
tion. Global gene expression analysis was conducted by 
DNA microarray. Histopathology results were used to 
classify patients into fast responders and slow partial re-
sponders. Overexpression of the  CPI-17 gene (2.8-fold in-
crease, p = 0.039) and the  WDR72 gene (1.9-fold increase, 
p = 0.040) was detected in fast responders. The authors 
concluded that 1-month treatment with the medical de-
vice containing photolyase improved the field of cancer-
ization and restored normal phenotype in at least a subset 
of samples, as shown by  CPI-17 upregulation – a gene 
involved in normal phenotype recovery  [39] .
 In a longitudinal, observational clinical trial from Bra-
zil, 14 patients (8 men and 6 women, aged between 45 and 
65 years) with grade I and grade II AK and other cutane-
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ous signs of actinic damage were prospectively studied 
 [40] . After selection the AK lesions were documented 
through clinical photography, optical polarized light der-
moscopy and reflectance CM in vivo. Patients were in-
structed to apply daily the medical device containing pho-
tolyase and sunscreen SPF 100. After 120 days, new clini-
cal photographic documentation, optical polarized light 
dermoscopy and in vivo CM were carried out. The im-
ages obtained before and after treatment were compared. 
A total of 17 AK lesions, 14 grade I and 3 grade II, were 
documented with clinical photographs and dermoscopy 
before and after 120 days of cream use. Of the 14 AK grade 
I lesions, 9 showed clinical improvement with a reduction 
of erythema and desquamation in dermoscopic evalua-
tion; 3 remained unchanged and 1 AK lesion evolved into 
grade II. All 3 grade II AK showed no clinical and dermo-
scopic improvement after 120 days of cream use. In addi-
tion, 8 of these lesions were studied by CM in vivo. Of 
these, 5 were AK grade I and 3 grade II. All patients with 
grade I AK showed decreased scaling and improved stan-
 Table 1.  Summary of clinical studies with a medical device containing DNA repair enzyme photolyase and high SPF sunscreen
Study Participants Treatment Duration Assessment Efficacy/findings
Puig [38],
2014
M:F 12:1, XP 2 patients
Mean age: 72 years
FST I:II:III:IV 1:7:3:2
AK in area larger than
3.6 × 3.6 cm affected by 
multiple AK lesions in 
a sun-exposed skin area
Photolyase 
encapsulated in 
liposomes with 
high SPF SS, 
n = 9
Control, SS 
cream, n = 3
4 weeks Clinical dermoscopy
Reflectance CM
Histology
Immunohistochemistry
Improved erythema and scaling (p = 0.03) in 
photolyase-treated group compared to SS
Decreased presence of scaling, detached 
corneocytes and polygonal nucleated cells in 
the stratum corneum
Histological clearance in 4 patients and 
improvement with focal AK associated with 
inflammation in 3 patients
Decreased p21 and PCNA expression in 
suprabasal layers
Puig-Butille 
[39], 2013
M:F 12:1, XP 2 patients
Mean age: 72 years
FST I:II:III:IV 1:7:3:2
AK in area larger than
3.6 × 3.6 cm affected by 
multiple AK lesions in 
a sun-exposed skin area
Photolyase 
encapsulated in 
liposomes with 
high SPF SS, 
n = 7
Control, SS 
cream, n = 3
4 weeks, 
2×/day
RNA extracted from 
3-mm punch biopsies 
and histopathological 
evaluation from 2 areas 
before and after 
treatment; global gene 
expression analysis by 
DNA microarray and 
confirmation by RT-PCR
Histopathologically classified patients into 
fast responders and slow-partial responders
Overexpression of CPI-17 gene (2.8-fold 
increase, p = 0.039) and WDR72 gene (1.9-
fold increase, p = 0.040) in subgroup of fast 
responders
Puviani [36],
2013
6 case reports 
All male
Age: 65 – 75 years
FST II
Visible AK in face or 
on scalp
Photolyase 
encapsulated in 
liposomes with 
high SPF SS as 
adjuvant or 
single therapy
4 – 8 weeks Clinical assessment with 
photodocumentation
The majority of AK lesions clinically 
disappeared
Guistini [37],
2014
8 XP patients
M:F 3:5
Mean age: 55 years
FST II:III 6:2
Photolyase 
encapsulated in 
liposomes with 
high SPF SS as 
only therapy, 
n = 8
12 months Rate of new skin lesions 
(AK, BCC and SCC) 
during active treatment 
with product and during 
12 months just before the 
use of the product
65% reduction in appearance of new AK 
lesions
56% and 100% reductions in the incidence of 
new BCC and SCC lesions, respectively
Rstom [40],
2014
14 patients 
M:F 8:6
Age: 45 – 65 years 
Grade I and grade II 
AK and other 
cutaneous signs of 
actinic damage
Photolyase 
encapsulated in 
liposomes with 
high SPF SS
120 days,
daily 
application
AK lesions documented 
by clinical photography, 
optical polarized light 
dermoscopy and CM in 
vivo
17 AK, 14 grade I and 3 grade II lesions
Of grade I lesions, clinical and dermoscopic 
improvement with reduction of erythema 
and desquamation in 9 lesions; 3 remained 
unchanged and 1 progressed to grade II
Of 8 AK lesions examined by CM, 5 were 
grade I and 3 grade II; grade I AK showed 
decreased scaling and improved standard 
structural epidermal examination; no 
improvement was seen of grade II lesions
 FST = Fitzpatrick skin type; SS = sunscreen.
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dard epidermal structure. The 3 patients with grade II AK 
did not show any improvement after 120 days of treat-
ment. The authors concluded that the use of topical cream 
containing photolyase and sunscreen showed improved 
results of grade I AK and field cancerization as evaluated 
by clinical dermoscopy and CM.
 Conclusion 
 Taken together, there is evidence from the studies 
mentioned above and listed in  table 1 to indicate that the 
use of medical devices containing the DNA repair en-
zyme photolyase combined with a very high UV protec-
tion is beneficial in patients with AK because it can reduce 
field cancerization and the occurrence of new AK. The 
majority of these studies involved small numbers of pa-
tients. In fact, a large, controlled, randomized, double-
blinded study in DNA repair-proficient, immunocompe-
tent individuals to show the efficacy of photolyase-con-
taining medical devices in the prevention of AK and the 
treatment of field cancerization is currently lacking. The 
experts, however, acknowledge the fact that such a study, 
although highly desirable, is extremely difficult to per-
form given the fact that photocarcinogenesis in humans 
is a process involving many years. In view of the ongoing 
and anticipated increase in AK numbers, the group, 
therefore, proposes an algorithm for its prevention as de-
scribed in  figure 1 , balancing the category of evidence 
available and the strength of recommendation as per the 
guidelines for developing clinical guidelines according to 
Shekelle et al.  [41] , where the category of evidence varies 
from IA to IV – category IA being the one with most clin-
ical evidence available in the form of meta-analysis of ran-
domized, controlled trials. The strength of recommenda-
tion varies from grades A to D, with grade A being the 
strongest level of recommendation which takes into ac-
count the category of evidence and other additional fac-
tors. Briefly, persons with Fitzpatrick phototype III or 
higher with no family or personal history of NMSC are at 
low risk for photodamage. In this population the use of 
photoprotection during summer is probably sufficient 
(level of evidence IIb, grade of recommendation B). Per-
sons considered at moderate risk, for example those with 
phototype I and II, a personal or family history of NMSC 
or elevated work-related sun exposure, could be recom-
mended the all-year-round use of a high-quality sun-
screen product SPF >50 with a balanced UVA and UVB 
protection spectrum (level of evidence IIb, grade of rec-
ommendation B). However, persons at high or very high 
risk should be recommended the year-round use of a 
medical device that, in addition to very high photoprotec-
? Low risk? Moderate?
risk ?
High??
risk?
Very?
high risk?
Description of
???????????
? ?????????????????
?????????
?????????????????
??????????????????
????????
?????????????????
???????????
??????????????????
?????
Fitzpat?????ski????p??<???
and/o???????ive ??????
????????o??NM??
and/o?????k??????????
[sun?????history????????
???????t???????????????
??ot??wor??an???????re)]?
?????????o??AK
Histor??o????
??????ent
Positiv??????????o????
and/??????????
???? ???o?????????
????????
??????????????????ic?????
?????????????????????
?????????o?? ore
?????1?????lesions
wi???fiel??
cancerization
????????????la???
recipients
? ?unosupp???????
????ec???
(iatrogeni???
noniatrogenic)
????????n???
?
Photoprotection
???????er
???????????grad??B??
Photoprotect????????year
??????wit?????????
??????????r???????oul??
???good
(lev?????????ad??B)
?
Ver????????hotoprotectio??and?
photorepai??actio??(DN???e??????????????
i?? ???????????????roduc???????yea??round
?????????????ad?????
Risk
categories
???????????
?????????
?????????
photoprotection?
 Fig. 1. Adjuvant treatment algorithm. Cosmetic product: this med-
ical device category of products differs from common sunscreens 
in that whereas common cosmetic sunscreens are subject to the 
European Commission recommendation and do not require an 
external certification, a medical device class II is certified by an 
independent notified body and fulfills the European requirements 
for a medical device class II. 
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tion (SPF  ≥ 100), contains DNA repair enzymes with the 
potential to actually reverse photo-induced DNA dam-
age. High-risk groups can be defined as persons with AK 
or recently treated for AK, positive history of AK or 
NMSC or clinically relevant photodamage. The very-
high-risk population, comprising organ transplant recip-
ients, immunosuppressed patients (both iatrogenic and 
noniatrogenic), XP patients, and patients with 10 or more 
AK lesions, should be strongly recommended the use of 
these medical devices that offer more than photoprotec-
tion (level of evidence IIa, grade of recommendation A). 
We consider that in this very-high-risk group of patients 
the level of recommendation should be rated A, despite 
lacking a level of evidence Ia, in view of the substantial 
clinical risk of developing skin cancer. A photoprotection 
and also photorepair strategy could therefore be consid-
ered as mandatory. Very recently, Premi et al.  [42] have 
demonstrated that in melanocytes the generation of CPD 
could be induced also >3 h after UV exposure (‘dark’ 
CPD). This mechanism seems to be mediated by the oxi-
dation of melanin, which in turn induces CPD formation 
in a radiation-independent manner, suggesting that mel-
anin may be a carcinogen as well as being protective 
against skin cancer. These data further underline the po-
tential relevance and importance of DNA photorepair 
mechanisms in order to reduce the risk of actinic damage 
and skin cancer.
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